BIO-B vs TECH

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of just 2/9, indicating significant deterioration in fundamental performance. Despite a strong balance sheet (Current Ratio: 5.44, Debt/Equity: 0.21), the company is unprofitable (Profit Margin: -26.43%, ROE: -9.50%) and lacks meaningful valuation metrics due to negative earnings. While quarterly earnings have beaten estimates 3 out of 4 times recently, revenue growth is nearly flat (0.50% YoY), and long-term price performance remains deeply negative (-47.0% over 5 years). The absence of Altman Z-Score and Graham Number prevents a full value assessment, but current fundamentals do not support a bullish stance.

Bio-Techne exhibits exceptional financial health with a Piotroski F-Score of 8/9 and a very low Debt/Equity ratio of 0.17. However, there is a massive disconnect between the current price ($60.58) and deterministic value metrics, such as the Graham Number ($12.40) and Intrinsic Value ($10.94). While the PEG ratio of 0.76 and forward P/E of 27.99 suggest growth potential that justifies a premium, stagnant revenue growth (-0.40%) and bearish technical trends temper the outlook. The stock is a high-quality company trading at a significant growth premium.